
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics is positioned for success, with a promising pipeline of genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. The recent results from the Phase 3 ALPHA3 trial demonstrate the effectiveness of their lead candidate, cema-cel, in achieving MRD-negative rates and a manageable safety profile in patients with MRD+ DLBCL. These results, combined with the potential market opportunity in the community setting and the company's focus on deliverability and access attributes, could position Allogene as a leader in the CAR-T space. While there are risks to achieving their price target, the early data suggests a favorable outcome for Allogene's lead candidate and the company's future success.
Bears say
Allogene Therapeutics is heavily reliant on partners for access to gene-editing technology and may face risks of partner termination, underscoring the company's financial instability in a heavily competitive CAR-T cell therapeutic market. Despite a well-funded current state, additional equity financing may be required, posing potential dilution risks for investors. Additional issues include clinical risk, including the inherent risk of CAR-T therapies, potential failure of clinical trials, and regulatory and commercial risks, which depend on timely approval from regulatory agencies.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares